{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.763","upperLimit":"0.910","value":"0.837"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"102"}],"units":"Participants"}],"description":"Progression-free Survival was defined as time from study entry to disease progression or recurrence. Deaths that are clearly unrelated to disease progression, and second neoplasms are censored in this analysis. Progression -free survival was estimated by KM estimate.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients will receive 6 cycles of Induction chemotherapy consisting of carboplatin and etoposide (Cycles 1, 3, and 5) alternating with ifosfamide and etoposide (Cycles 2, 4, and 6). The entire length of Induction is 18 weeks unless delay occurs due to myelosuppression or unanticipated toxicity. Each cycle of Induction will begin when ANC \\> 750/L and platelets \\> 75,000/L and when off filgrastim (G-CSF) for at least 48 hours. Following the Induction phase (weeks 0-18) those patient in CR will undergo radiation therapy.\n\ncarboplatin: Given IV\n\netoposide: Given IV\n\nifosfamide: Given IV\n\nthiotepa: Given IV\n\nadjuvant therapy\n\nconventional surgery\n\nneoadjuvant therapy\n\nperipheral blood stem cell transplantation\n\nradiation therapy: craniospinal irradiation","id":"OG000","title":"Radiation Therapy (CR From Induction)"}],"paramType":"NUMBER","populationDescription":"Two ineligible patients were excluded. A total of 102 eligible patients were analyzed. one patient died without the disease progression reported. But the death was due to the disease. The death was counted as \"event\" when progression-free survival (PFS) was calculated. So EFS and PFS at 3 years were same.","reportingStatus":"POSTED","timeFrame":"At 3 years from study entry","title":"Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Probability"}